Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161–176.
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–71.
Article
Google Scholar
World Health Organization. Global hepatitis report, 2017. Geneva: WHO; 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf. Accessed 6 Dec, 2018
Google Scholar
WHO. Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries. Geneva: World Health Organization; 2018.
Google Scholar
Muyldermans G, Van Gucht S, Van Baelen L. Jaarrapport 2016: hepatitis C virus; Wetenschappelijk Instituut Volksgezondheid - Institution Scientifique de santé Publique (WIV-ISP). https://nrchm.wiv-isp.be/nl/ref_centra_labo/hepatitis/Rapporten/Rapport%20HCV%202016.pdf. Accessed 6 Dec, 2018.
Van Damme P, Laleman W, Stärkel P, et al. Hepatitis C epidemiology in Belgium. Acta Gastroenterol Belg. 2014;77:277–9.
PubMed
Google Scholar
Federale Overheidsdienst Volksgezondheid. Veiligheid van de voedselketen en Leefmilieu: Protocolakkoord 'HCV-plan'. Belgisch staatsblad- Moniteur Belge,. In. Brussels; 2014. p. 57926–40. [C-2014/24267]
Google Scholar
Mulkay JP: National Hepatitis Plan Belgium. 2017 Viral hepatitis Prevention Board country meeting Belgium, Brussels. http://www.vhpb.org/files/html/Meetings_and_publications/Presentations/BRUS81.pdf. Accessed 5 Jan, 2018.
De Raedt L. Introduction to the Belgian Health System. 2017 Viral Hepatitis Prevention Board country meeting Belgium. http://www.vhpb.org/files/html/Meetings_and_publications/Presentations/BRUS21.pdf. Accessed 6 Dec, 2018.
Lazarus JV, Wiktor S, Colombo M, Thursz M, Foundation EIL. Micro-elimination – a path to global elimination of hepatitis C. J Hepatol. 2017;67(4):665–6.
Article
PubMed
Google Scholar
Lazarus JV, Safreed-Harmon K, Thursz MR, et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin Liver Dis. 2018;38(3):181–92.
Article
PubMed
Google Scholar
Control ECfDPa. Surveillance Atlas of Infectious Diseases. 2018; https://ecdc.europa.eu/en/surveillance-atlas-infectious-diseases, 2018.
Sasse A et al. Epidemiologie van AIDS en HIV Infectie in België 2014. Wetenschappelijk Instituut Volksgezondheid (WIV-ISP), https://epidemio.wiv-isp.be/ID/reports/Jaarrapport_HIV-AIDS_2014.pdf/. Accessed 1 Jan, 2018.
Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797–808.
Article
PubMed
Google Scholar
Bieber B, Goodkin DA, Nwankwo N, et al. Hepatitis C prevalence and clinical outcomes in the Dialysis Outcomes and Practice Patterns study. Nephrol Dial Transplant. 2015;30(suppl 3):iii314.
Article
Google Scholar
Office of the Commissioner General for Refugees and Stateless persons (CGRS) Belgium: Year report 2016. https://www.cgvs.be/nl/cijfers?field_cijfers_month_year_value%5Bvalue%5D%5Byear%5D=2016. Accessed 12 Dec, 2018.
Robaeys G, Van Vlierberghe H, Mathei C, Van Ranst M, Bruckers L, Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Gastroenterol Hepatol. 2006;18(2):159–66.
CAS
Google Scholar
Mauss S, Pol S, Buti M, et al. Late presentation of chronic viral hepatitis for medical care: a consensus definition. BMC Med. 2017;15(1):92.
Article
PubMed
PubMed Central
Google Scholar
Bollaerts K, Aerts M, Sasse A. Improved benchmark-multiplier method to estimate the prevalence of ever-injecting drug use in Belgium, 2000-10. Arch Public Health. 2013;71(1):10.
Article
PubMed
PubMed Central
Google Scholar
Bielen R, Moreno C, Van Vlierberghe H, et al. Belgian experience with direct acting antivirals in people who inject drugs. Drug Alcohol Depend. 2017;177:214–20.
Article
CAS
PubMed
Google Scholar
Matheï CBS, Brixko C, Blach S, Mulkay JP, Razavi H, Robaeys G. The modeled impact of improved Hepatitis C Virus (HCV) treatment strategies on HCV prevalence among people who inject drugs (PWIDs) in Belgium. Abstract presented at. San-Francisco: AASLD; 2015.
Google Scholar
Lazarus J, Pericàs J, Colombo M, Ninburg M, Wiktor S, Thursz M. Viral hepatitis: “E” is for equitable elimination. J Hepatol. 2018;69(4):762–4.
Article
PubMed
Google Scholar
Marshall AD, Pawlotsky JM, Lazarus JV, Aghemo A, Dore GJ, Grebely J. The removal of DAA restrictions in Europe – one step closer to eliminating HCV as a major public health threat. J Hepatol. 2018;69(5):1188–96.
Article
PubMed
Google Scholar
Marshall AD, Cunningham EB, Nielsen S, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018;3(2):125–33.
Article
PubMed
Google Scholar
Belgian Association for Study of the Liver [website]. In Hepatitis C: cut-off’s elastography and biological testing for METAVIR F3-F4 and treatment options in BELGIUM: update 01/06/2018. 2018. Available at: http://www.basl.be/hcvguidelinesbelgium.
Google Scholar
Antivirale geneesmiddelen tegen hepatitis C: vergoedingsvoorwaarden vanaf 1 januari 2017 - RIZIV. 2018. http://www.riziv.fgov.be/nl/themas/kost-terugbetaling/door-ziekenfonds/geneesmiddel-gezondheidsproduct/terugbetalen/specialiteiten/wijzigingen/Paginas/antiretrovirale_hepatitisc_terugbetalingsvoorwaarden_20170101.aspx#.Ww0_40iFNPY. Accessed 29 May, 2018.
Antivirale geneesmiddelen tegen hepatitis C: vergoedingsvoorwaarden vanaf 1 januari 2019 - RIZIV. 2019. https://www.inami.fgov.be/nl/themas/kost-terugbetaling/door-ziekenfonds/geneesmiddel-gezondheidsproduct/terugbetalen/specialiteiten/wijzigingen/Paginas/antivirale-hepatitisc-terugbetalingsvoorwaarden_20190101.aspx. Accessed 15 February, 2019.
Crown W, Buyukkaramikli N, Thokala P, et al. Constrained optimization methods in health services research-an introduction: report 1 of the ISPOR optimization methods emerging good practices task force. Value Health. 2017;20(3):310–9.
Article
PubMed
Google Scholar
Lazarus JV, Stumo SR, Harris M, et al. Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017. J Intern AIDS Soc. 2018;21:e25052.
Article
Google Scholar
Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology. 2002;36(5 Suppl 1):S106–13.
PubMed
Google Scholar
Tovo PA, Calitri C, Scolfaro C, Gabiano C, Garazzino S. Vertically acquired hepatitis C virus infection: correlates of transmission and disease progression. World J Gastroenterol. 2016;22(4):1382–92.
Article
CAS
PubMed
PubMed Central
Google Scholar
Apers L, Koole O, Bottieau E, et al. Incidence of HCV and sexually transmitted diseases among HIV positive MSM in Antwerp, Belgium, 2001-2011. Acta Clin Belg. 2013;68(6):421–6.
Article
CAS
PubMed
Google Scholar
Bottieau E, Apers L, Van Esbroeck M, Vandenbruaene M, Florence E. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009. Euro Surveill. 2010;15(39):19673.
CAS
PubMed
Google Scholar
Botterman R, Glorieus E, Lefere S, et al. Do or don’t: HCV screening in the Belgian Baby Boom Cohort. In: BWGE2017; 2017; Antwerp. https://bwge2017.sched.com/event/9DfC/do-or-dont-hcv-screening-in-the-belgian-baby-boom-cohort, accessed 6 Dec, 2018.
Bielen R, Kremer C, Koc Ö, et al. Screening for hepatitis C at the emergency department: should baby boomers also be screened in Belgium? Liver Int. 2018;39(4):667–75.
Article
PubMed
CAS
Google Scholar
Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19(4):904–9.
Article
PubMed
Google Scholar
Stuyver L, Claeys H, Wyseur A, et al. Hepatitis C virus in a hemodialysis unit: molecular evidence for nosocomial transmission. Kidney Int. 1996;49(3):889–95.
Article
CAS
PubMed
Google Scholar
Wheeler D, Winkelmayer WC. The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008;73(Suppl 109):1–99.
Google Scholar
Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013;38(5):405–12.
Article
CAS
PubMed
Google Scholar
Goodkin DA, Bieber B, Jadoul M, Martin P, Kanda E, Pisoni RL. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin J Am Soc Nephrol. 2017;12(2):287–97.
Article
PubMed
Google Scholar
Jadoul M, Berenguer MC, Doss W, et al. Executive summary of the 2018 KDIGO hepatitis C in CKD guideline: welcoming advances in evaluation and management. Kidney Int. 2018;94(4):663–73.
Article
PubMed
Google Scholar
ECDC technical report: Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA. 2016. https://ecdc.europa.eu/en/publications-data/epidemiological-assessment-hepatitis-b-and-c-among-migrants-eueea. Accessed 5 Jan, 2018.
Starkel P, Vandijck D, Laleman W, et al. The disease burden of hepatitis C in Belgium: development of a realistic disease control strategy. Acta Gastroenterol Belg. 2014;77(2):280–4.
CAS
PubMed
Google Scholar
WHO Collaborating Center for Drug Statistics Methodology. Definition and general considerations of defined daily dose (DDD). https://www.whocc.no/ddd/definition_and_general_considera/. Accessed 14 Mar, 2018.
EASL. Recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–94. https://doi.org/10.1016/j.jhep.2016.09.001 Accessed 6 Dec, 2018.
Article
Google Scholar
Mathei C, Bourgeois S, Blach S, et al. Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium. Acta Gastroenterol Belg. 2016;79(2):227–32.
CAS
PubMed
Google Scholar
Walmsley R. World prison population list (11th edition). World Prison Brief 2015; http://www.prisonstudies.org/sites/default/files/resources/downloads/world_prison_population_list_11th_edition_0.pdf. Accessed 7 Dec, 2018.
Google Scholar
Pawlotsky J-M, Negro F, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511.
Article
Google Scholar
Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014;21(Suppl 1):34–59.
Article
PubMed
Google Scholar
Sokal E, Nannini P. Hepatitis C virus in children: the global picture. Arch Dis Child. 2017;102(7):672–5.
Article
Google Scholar
El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol. 2013;19(44):7880–8.
Article
PubMed
PubMed Central
CAS
Google Scholar
Pawlowska M, Domagalski K, Pniewska A, Smok B, Halota W, Tretyn A. What's new in hepatitis C virus infections in children? World J Gastroenterol. 2015;21(38):10783–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vanhaesebrouck P, Roelens K, De Praeter C, Robberecht E, Goossens L, Leroux-Roels G. Aanpak bij perinatale hepatitis C-virusinfectie. Tijdschrift voor Geneeskunde. 2006;62(16):1124–8.
Article
Google Scholar
European Union HCV Collaborators. Hepatitis C virus prevalence and level ofintervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325–36.
Article
Google Scholar
Pascasio JM, Vinaixa C, Ferrer MT, et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol. 2017;67(6):1168–76.
Article
PubMed
Google Scholar
Chhatwal J, Samur S, Kues B, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017;65(3):777–88.
Article
PubMed
Google Scholar
Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65(3):524–31.
Article
PubMed
Google Scholar
Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16(6):685–97.
Article
CAS
PubMed
Google Scholar
Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649–59.
Article
CAS
PubMed
Google Scholar
Franchini M, Tagliaferri A, Rossetti G, et al. The natural history of hepatitis C virus infection in hemophiliacs. Hematology. 2001;6(2):135–42.
Article
CAS
PubMed
Google Scholar
Fransen van de Putte DE, Makris M, Fischer K, et al. long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. J Hepatol 2014;60(1):39–45.
Irish Haemophilia Society: treatment for hepatitis c; press release 2016. https://haemophilia.ie/hiv-hepatitis-c/hepatitis-c-2/treatment-for-hepatitis-c/. Accessed 5 Jan, 2018.
Jadoul M. Transmission routes of HCV infection in dialysis. Nephrol Dial Transplant. 1996;11(1):36–8.
Article
PubMed
Google Scholar
Goldberg D, Ditah IC, Saeian K, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology. 2017;152(5):1090–9 e1091.
Article
PubMed
Google Scholar
Fernandez Carrillo C, Lens S, Llop E, et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C registry. Hepatology. 2017;65(6):1810–22.
Article
CAS
PubMed
Google Scholar
Ingiliz P, Martin TC, Rodger A, et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol. 2017;66(2):282–7.
Article
PubMed
Google Scholar
Gore C, Lazarus JV, Baptista Leite R, et al. Road to elimination: barriers and best practices in hepatitis C management: overview of the status of HCV care in Europe and Australia. Boston Consulting Group, 2017. http://image-src.bcg.com/Images/BCG-Road-to-Elimination_tcm104-166034.pdf. Accessed 5 Jan, 2018.
Apers L, Vanden Berghe W, De Wit S, et al. Risk factors for HCV acquisition among HIV-positive MSM in Belgium. J Acquir Immune Defic Syndr. 2015;68(5):585–93.
Article
PubMed
Google Scholar
Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(RR-4):1–32.
PubMed
Google Scholar
Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156(4):263–70.
Article
PubMed
Google Scholar
US Department of Health and Human Services. Combating the silent epidemic of viral hepatitis: action plan for the prevention, care, and treatment of viral hepatitis. HHS. Washington: HHS; 2011. p. 1–76.
Google Scholar
Trias-Llimos S, Bijlsma MJ, Janssen F. The role of birth cohorts in long-term trends in liver cirrhosis mortality across eight European countries. Addiction. 2017;112(2):250–8.
Article
PubMed
Google Scholar
Falla AM, Ahmad AA, Duffell E, Noori T, Veldhuijzen IK. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries. BMC Infect Dis. 2018;18(1):42.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sharma S, Carballo M, Feld J, Janssen H. Immigration and viral hepatitis. J Hepatol. 2015;63(2):515–22.
Article
PubMed
Google Scholar
Grebely J, Bruneau J, Lazarus JV, et al. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Int J Drug Policy. 2017;47:51–60.
Article
PubMed
PubMed Central
Google Scholar
European Centre for Disease Prevention and Control (ECDC). Annual epidemiological report 2016 – hepatitis C. Stockholm: ECDC; 2016.
Google Scholar
Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285–301.
Article
PubMed
Google Scholar
Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1):74–83.
Article
PubMed
PubMed Central
Google Scholar
MacArthur GJ, van Velzen E, Palmateer N, et al. Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25(1):34–52.
Article
PubMed
Google Scholar
Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978–88.
Article
PubMed
Google Scholar
Platt L, Minozzi S, Reed J, et al. Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018;113(3):545–63. https://doi.org/10.1111/add.14012 [Epub ahead of print]).
Article
PubMed
Google Scholar
Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10):1099–109.
Article
PubMed
PubMed Central
Google Scholar
Morris MD, Shiboski S, Bruneau J, et al. Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: the InC3 collaboration. Clin Infect Dis. 2017;64(7):860–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wiessing L, Ferri M, Grady B, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014;9(7):e103345.
Article
PubMed
PubMed Central
CAS
Google Scholar
Roy E, Nonn E, Haley N, Cox J. Hepatitis C meanings and preventive strategies among street-involved young injection drug users in Montréal. Int J Drug Policy. 2007;18(5):397–405.
Article
PubMed
Google Scholar
Bielen R, Verrando R, Penders J, Oris E, Nevens F, Robaeys G. Case management to improve uptake for screening and therapy of hepatitis C viral infection in people who inject drugs. Hepatology. 2016;64(1 Suppl):411A–2A.
Google Scholar
Dolan K, Wirtz AL, Moazen B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089–102.
Article
PubMed
Google Scholar
Altice FL, Azbel L, Stone J, et al. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016;388(10050):1228–48.
Article
PubMed
PubMed Central
Google Scholar
Richardson D, Fisher M, Sabin CA. Sexual transmission of hepatitis C in MSM may not be confined to those with HIV infection. J Infect Dis. 2008;197(8):1213–4 author reply 1214–1215.
Article
PubMed
Google Scholar
van de Laar TJ, Paxton WA, Zorgdrager F, Cornelissen M, de Vries HJ. Sexual transmission of hepatitis C virus in human immunodeficiency virus-negative men who have sex with men: a series of case reports. Sex Transm Dis. 2011;38(2):102–4.
Article
PubMed
Google Scholar
Volk JE, Marcus JL, Phengrasamy T, Hare CB. Incident hepatitis C virus infections among users of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;60(11):1728–9.
Article
PubMed
PubMed Central
Google Scholar
Hoornenborg E, Achterbergh RCA. Schim Van Der Loeff MF, et al. men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study. AIDS. 2017;31(11):1603–10.
Article
PubMed
Google Scholar
Saludes V, Folch C, Morales-Carmona A, et al. Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: analysis of key populations in Barcelona. Spain J Viral Hepat. 2018;25(3):236–44.
Article
CAS
PubMed
Google Scholar
Fraser H, Martin NK, Brummer-Korvenkontio H, et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol. 2018;68:402–11.
Article
PubMed
PubMed Central
Google Scholar
Dore G, Grebely J, Altice F, et al. Hepatitis C virus reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in participants on opiate agonist therapy: C-EDGE CO-STAR Part B. Washington, D.C: AASLD Annual Meeting; 2017.
Google Scholar